A Phase 4 interventional study of Mepolizumab 100 MG Injection [Nucala] and Mepolizumab 300 mg in EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma and Eosinophilic Asthma, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Azienda Ospedaliero Universitaria di Cagliari · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Churg-Strauss Syndrome with a site in Italy — 5 open to participants now, 7 under way, 2 of them phase 3. Churg-Strauss Syndrome · Italy.
Among the 13 studies in Churg-Strauss Syndrome with a site in Italy, this one is one of 4 that started in 2025, is the only one in phase 4, and was the 9th registered.
61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.
Browse Churg-Strauss Syndrome studies →5 of the 13 studies in Churg-Strauss Syndrome with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 6+
European EGPA Study Group · Sites in Italy
Ages 18+
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
University of Pennsylvania · Sites in Italy, United States, Canada and 2 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 66 across 30 interventional studies indexed under Churg-Strauss Syndrome.
Median enrollment 136 across the 7 interventional studies, 299 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero Universitaria di Cagliari is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Azienda Ospedaliero Universitaria di Cagliari has 1 study filed under Churg-Strauss Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Churg-Strauss Syndrome with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06046222NS Pharma, Inc.Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2026-12 |
| NCT07815886European EGPA Study GroupBenralizumab Effectiveness in EGPA | 2027-02-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Churg-Strauss Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of the study is to identify potential biomarkers, through a proteomic approach, which could be used to evaluate organ damage and predict the response to mepolizumab in a cohort of patients affected by EGPA. Proteomic analyses will be performed using a proteomic platform, based on a nano-HPLC- couplet to an high resolution ESI-MS device, on three types of biological matrices: blood, saliva and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different time points after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyze the effect of the therapy during treatment, assessing the disease progression on three key aspects: lung function and symptoms control, vasculitis and neuropathy. Plasma analysis will provide an overview of quantitative/qualitative proteomic variations at systemic level after drug administration; however, a less invasive procedure is often sufficient and would improve trial recruitment. On this regard, saliva is a biological fluid well suitable to be used in proteomic investigations for suggestion of potential disease biomarkers and includes various potential advantages compared with blood sample collection such as lower overall cost, lower infection risk, increased patient convenience, acceptability, compliance and uptake. Moreover, the protein composition of the human saliva includes both specific proteins of the oral cavity and proteins common to other tissues and bodily fluids, so saliva prognostic and diagnostic role is particularly interesting. Consequently, the plan is to compare the proteomic results of the non-invasive saliva testing to that of blood examination.
These data may be a further step to untangle the mechanisms of the disease and to characterize treatment's response, in the contest of a phenotype/endotype asthma management.
The investigators plan to collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.
untangle the mechanisms of the disease and to characterize response to treatment, in the context of a phenotype/endotype asthma and EGPA management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mepolizumab treatment
Drug: Mepolizumab 300 mg
immunosuppressive drugs (CYC, AZA, MTX) and/or Mepolizumab
Drug: Mepolizumab 300 mg
before and after Mepolizumab treatment
Drug: Mepolizumab 100 MG Injection [Nucala]
collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.
collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.
Saliva, sputum, and plasma proteomic profile of EGPA patients
Obtain a proteomic profile of EGPA patients and severe asthmatic patients from blood, saliva and sputum. Analyse the samples after starting anti IL - 5 treatment ( mepolizumab ) and evaluate the possible disease modifying effect of the mepoliumab on vas
Time frame: From the data to the enrollment until the end of the study, up to 52 weeks.
If it is possible to predict the response to treatment by analyzing the proteomic profile of the patients.
untangle the mechanisms of the disease and to characterize response to treatment, in the context of a phenotype/endotype asthma and EGPA management
Time frame: From date of randomization until the date of first documented progression, assessed up to 24 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — PRIVACY
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mepolizumab
Azienda Ospedaliero Universitaria di Cagliari